$GOVX to Present at the Noble Capital Markets Emerging Growth Equity Conference December 3, 2024. Video webcast available the following day on https://t.co/sgQptNghWl #mpox#immunocompromised#mva
$GOVX milestones met, including plans for a Phase 2 trial of Gedeptin for first recurrent head and neck cancer in combination with an immune checkpoint inhibitor. Full report here. https://t.co/6w65PetLsA
Join BioUtah & the UK government for a FREE webinar on navigating the UK health market & accessing innovation support.
https://t.co/fS3SBihPau #utah#UK#MoU#lifesciences#UKMoUhealth@BioUtah
It has been shown that an effective T cell response is associated with less severe
COVID-19 and this response is much more durable over time than the antibody-mediated
response [16]. #vaccines#COVID19#immunocompromised#MVA $GOVX https://t.co/FrAcoJ7h5C